Details for Patent: 9,283,209

Which drugs does patent 9,283,209 protect, and when does it expire?

Patent 9,283,209 protects JADENU and is included in one NDA.

This patent has sixty-seven patent family members in forty-two countries.

Summary for Patent: 9,283,209

Title:	Oral formulations of deferasirox
Abstract:	Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
Inventor(s):	Ghosh; Indrajit (Hillsborough, NJ), Zhang; Jia-Ai (Skillman, NJ)
Assignee:	NOVARTIS AG (Basel, CH)
Application Number:	14/198,872
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,283,209
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 9,283,209

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No			Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No			Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,283,209

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095058
Australia	2014224198
Australia	2017203897
Brazil	112015021254
Canada	2890465